In combination with the BD OneFlow™ LST, it is intended as an aid in the diagnosis of chronic lymphocytic leukemia (CLL) and other B cell chronic lymphoproliferative diseases.
Overview
The BD OneFlow™ B-CLPD T1 is part of the innovative BD OneFlow™ Solution, a comprehensive set of reagents, setup beads, protocols and assay templates to reproducibly set up the flow cytometer and stain, acquire and analyze patient specimens for immunophenotyping of normal and aberrant cell populations. It is built on the research and validation work of the EuroFlow™ Consortium on the characterization of hematological malignancies for improved accurate diagnosis.1*
The BD OneFlow™ B-CLPD T1 is intended for flow cytometric immunophenotyping of B cells in peripheral blood and bone marrow as an aid in the diagnosis of chronic lymphocytic leukemia (CLL) and other B cell chronic lymphoproliferative diseases.
Other reagents belonging to the BD OneFlow™ Solution are BD OneFlow™ Lymphoid Screening Tube (LST), BD OneFlow™ Plasma Cell Screening Tube (PCST), BD OneFlow™ Plasma Cell Disorders (PCD) Tube and BD OneFlow™ Acute Leukemia Orientation Tube (ALOT).
View video describing the BD OneFlow™ Solution on the BD FACSLyric™ Flow Cytometer.
View videos below describing how standardization, efficiency, accuracy and reproducibility can be achieved using the BD OneFlow™ Solution on the BD FACSCanto™ II Flow Cytometer.
The BD OneFlow™ B-CLPD T1 reagent composition
| Antibody | Fluorochrome | Clone | Target Populations |
|---|---|---|---|
| CD23 | FITC | EBVCS-5 | Contributes to the classification of CLL or other B-cell chronic lymphoproliferative diseases |
CD10 | PE | MEM-78 | Contributes to the classification of CLL or other B-cell chronic lymphoproliferative diseases |
| CD79b | PerCP-Cy 5.5 | SN8 | Contributes to the classification of CLL or other B-cell chronic lymphoproliferative diseases |
| CD19 | PE-CY 7 | SJ25-C1 | Backbone marker. In common with BD OneFlow™ LST |
| CD200 | APC | MRC 0X-104 | Contributes to the classification of CLL or other B-cell chronic lymphoproliferative diseases |
| CD43 | APC-H7 | 1G10 | Contributes to the classification of CLL or other B-cell chronic lymphoproliferative diseases |
| CD20 | BD Horizon™ V450 | L27 | Backbone marker. In common with BD OneFlow™ LST |
| CD45 | BD Horizon™ V500-C | 2D1 | Backbone marker. In common with BD OneFlow™ LST |
The EuroFlow antibody panel article1* has a full description of the utility of the antibodies chosen for the BD OneFlow™ B-CLPD T1.
APPLICATIONS
Laboratory report of a normal bone marrow specimen stained with the 8-color 8-antibody BD OneFlow™ B-CLPD T1 single-test reagent acquired on the BD FACSLyric™ Flow Cytometer with BD FACSuite™ Clinical Application v1.4.
Laboratory report of an abnormal bone marrow specimen stained with the 8-color 8-antibody BD OneFlow™ B-CLPD T1 single-test reagent acquired on the BD FACSLyric™ Flow Cytometer with BD FACSuite™ Clinical Application v1.4.
Periodic and daily setup
-
Instructions for Use
-
Application Guides - For BD FACSLyric™ Flow Cytometer Users
-
Applications Guides - For BD FACSCanto™ II Flow Cytometer Users
-
Brochure
-
Tools
-
Application Note
-
Instructions for Use
-
Application Guides - For BD FACSLyric™ Flow Cytometer Users
-
Application Guides - For BD FACSCanto™ II Flow Cytometer Users
Standardization:
Reproducibility:
References
- van Dongen JJM, Lhermitte L, Böttcher S, et al. on behalf of the EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708). EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia. 2012;26(9): 1908-1975. doi: 10.1038/leu.2012.120
- Moloney E, Watson H, Barge D, et al. Efficiency and health economic evaluations of BD OneFlow™ Flow Cytometry Reagents for diagnosing chronic lymphoid leukemia. Cytometry B Clin Cytom. 2019;96(6):514-520. doi: 10.1002/cyto.b.21779
- Kalina T, Flores-Montero J, van der Velden VHJ, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986-2010. doi: 10.1038/leu.2012.122
